AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication
AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi’s Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product.
Datavant’s New Platform Could Cut Record Retrieval Time from Days to Hours
Datavant launched a new provider exchange platform, which replaces fax-based record requests with a digital workflow. It aims to give care teams real-time visibility into request status while easing the administrative burden on clinical staff.
Precision Medicine Transformed Oncology —It’s Time to Do the Same for Sepsis
It’s time we reignite treatment development for sepsis and other immune-mediated conditions that strike when patients are most vulnerable.
What Do the Latest Iteration of Consumer Drug Platforms Offer?
Consumer drug platforms and how they fit into the rise of the consumer in healthcare will be part of the conversation at INVEST Digital Health, scheduled for October 29 in Dallas. Register today!
Onos Health Raises $17M to Expand AI-Powered Behavioral Health Platform
Onos Health's Series A funding round was led by Costanoa, with support from Flare Capital Partners and CVS Health Ventures.